TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04331041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive stereotactic body radiation therapy
Description: * Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive stereotactic body radiation therapy
Description: * Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: -Oral drug 400 mg twice a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Baseline and 12-14 weeks after end of SBRT (or at time of surgery)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Research blood draw
Description: -Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
Study: NCT05796479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab DP1
Description: Injection solution 1~Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab DP1
Description: Injection solution 1~Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab DP2
Description: Injection solution 2~Subcutaneous
Study: NCT05533567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: The experimental group was sedated with remimazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was sedated with propofol.
Study: NCT06283186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise with lower limb cycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise with upper limb cycle ergometer
Study: NCT06069661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Stenosis
Description: F2 Filter and Delivery system to cover the 3 great cerebral vessels
Study: NCT05177055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based light therapy at gradually advanced timing for DSWPD
Description: Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based light therapy at gradually advanced timing for DSWPD
Description: Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses
Description: Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-week wait list for sleep-school
Description: Treatment as usual in a psychiatric outpatient clinic
Study: NCT05447702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion.
Study: NCT05432531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti JAK1,2
Description: Induction of remission of active lupus nephritis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamid
Description: Induction of remission of active lupus nephritis
Study: NCT04924426

Intervention type: PROCEDURE
Intervention: TTC immersion
Description: TTC immersion

Intervention type: PROCEDURE
Intervention: TTC immersion
Description: TTC immersion
Study: NCT05057364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Smart Virtual Self-Management Group
Description: The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
Study: NCT05799014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided percutaneous lung biopsy
Description: The participants would undergo CT-guided percutaneous lung biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology
Description: The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.
Study: NCT04825054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with NAVA mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with PCV mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with PSV mode
Description: To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform.
Study: NCT06487013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcBlate Focused Ultrasound Ablation System
Description: MR-guided High Intensity Focused Ultrasound (MRgHIFU)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham MRgHIFU treatment
Description: Sham MRgHIFU treatment
Study: NCT06302257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorprocaine
Description: we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Study participants will receive lidocaine alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-chlorprocaine combination
Description: study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
Study: NCT05850494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HFA MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Study: NCT06331624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene (GRI-0621)
Description: Oral 4.5mg soft gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral 4.5mg soft gel capsule
Study: NCT04902235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CRH administration
Description: CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo administration
Description: Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
Study: NCT05850494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFO MDI
Description: * Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA
Study: NCT05587946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
Study: NCT05542277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearPlasma
Description: ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ClearPlasma
Description: ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
Study: NCT06046742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M1-c6v1
Description: Intravenous drip administration
Study: NCT05330884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: 0.1ml BCg vaccine to be given intradermally

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Chemoprophylaxis
Description: Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
Study: NCT06272227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol
Description: Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: denosumab
Study: NCT06178068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of bronchodilator effectiveness of nebulizer therapy devices
Description: The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of bronchodilator effectiveness of nebulizer therapy devices
Description: The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of bronchodilator effectiveness of nebulizer therapy devices
Description: The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
Study: NCT05807009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core exercise
Description: the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
Study: NCT04911621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination + temozolomide-based chemoradiation
Description: 1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination +- conventional next-line treatment
Description: 1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition.
Study: NCT05833802

Intervention type: OTHER
Intervention: virtual anti-cancer drug
Description: the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
Study: NCT05763602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine topical ointment
Description: Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
Study: NCT04917926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and social incentives
Description: Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
Study: NCT05555004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST1
Description: Toddler milk with preconditioned L. reuteri and containing GOS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST 2
Description: Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
Study: NCT05495347

Intervention type: OTHER
Intervention: patients diagnosed with OSA
Description: All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
Study: NCT04840121

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AdhesioRT
Description: AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AdhesioRT
Description: AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
Study: NCT05015309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH3765 tablet
Description: Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
Study: NCT06199167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo Observation
Description: The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
Study: NCT04831632

Intervention type: DIAGNOSTIC_TEST
Intervention: quantitative and qualitative iFOBTs
Description: They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
Study: NCT05568771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Exercises Assisted Injury Prevention Training Program
Description: After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
Study: NCT05830383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDCA circular management
Description: PDCA circular management means PlanDoCheckAction four steps
Study: NCT05300087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Inhalation Aerosol 108mcg per actuation
Description: MDI, 2 puffs, single dose, fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation
Description: MDI, 2 puffs, single dose, fasting